Long-term clinical safety of the Ad26.ZEBOV and MVA-BN-Filo Ebola vaccines: a prospective, multi-country, observational study

Long-term clinical safety of the Ad26.ZEBOV and MVA-BN-Filo Ebola vaccines: a prospective, multi-country, observational study

In this prospective, observational study (ClinicalTrials.gov Identifier: NCT02661464), long-term safety information was collected from participants previously exposed to the Ebola vaccines Ad26.ZEBOV and/or MVA-BN-Filo while enrolled in phase 1, 2, or 3 clinical studies. The study was conducted at 1...

Full description

Bibliographic Details
Main Authors:	Puri, A, Pollard, AJ, Schmidt-Mutter, C, Lainé, F, PrayGod, G, Kibuuka, H, Barry, H, Nicolas, J-F, Lelièvre, J-D, Sirima, SB, Kamala, B, Manno, D, Watson-Jones, D, Gaddah, A, Keshinro, B, Luhn, K, Robinson, C, Douoguih, M
Other Authors:	EBL4001 Study Group
Format:	Journal article
Language:	English
Published:	MDPI 2024

Similar Items

Long-Term Clinical Safety of the Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: A Prospective, Multi-Country, Observational Study
by: Adeep Puri, et al.
Published: (2024-02-01)

Lot-to-lot consistency, immunogenicity, and safety of the Ad26.ZEBOV, MVA-BN-Filo Ebola virus vaccine regimen: A phase 3, randomized, double-blind, placebo-controlled trial
by: Neil Goldstein, et al.
Published: (2024-12-01)

Assessments of different batches and dose levels of a two-dose Ad26.ZEBOV and MVA-BN-Filo vaccine regimen
by: Viki Bockstal, et al.
Published: (2021-12-01)

Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola
by: Viki Bockstal, et al.
Published: (2022-11-01)

Durability of immune responses induced by three leading candidate ebola vaccine regimes; rVSV ZEBOV, ChAd3 EBO Z-MVA BN-Filo and AdHu26.ZEBOV-MVA BN Filo
by: Ewer, K, et al.
Published: (2018)

Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa
by: Barry, H, et al.
Published: (2021)

Prediction of long-term humoral response induced by the two-dose heterologous Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola
by: Marie Alexandre, et al.
Published: (2023-11-01)

Safety and immunogenicity of heterologous Ad26.ZEBOV and MVA-BN®-Filo prime-boost Ebola vaccines: 6-month follow-up of a Phase I randomized trial in healthy adults
by: Macaya Douoguih, et al.
Published: (2016-05-01)

Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial
by: Zacchaeus Anywaine, et al.
Published: (2022-01-01)

Identification of early gene expression profiles associated with long-lasting antibody responses to the Ebola vaccine Ad26.ZEBOV/MVA-BN-Filo
by: Fabiola Blengio, et al.
Published: (2023-09-01)

Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa
by: Houreratou Barry, et al.
Published: (2021-10-01)

Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa.
by: Houreratou Barry, et al.
Published: (2021-10-01)

The Effect of Previous Exposure to Malaria Infection and Clinical Malaria Episodes on the Immune Response to the Two-Dose Ad26.ZEBOV, MVA-BN-Filo Ebola Vaccine Regimen
by: Daniela Manno, et al.
Published: (2023-08-01)

Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN®-Filo Ebola vaccine regimen: a phase 2 randomised clinical study in Europe (EBOVAC2)
by: Pollard, AJ, et al.
Published: (2020)

First-in-human study to evaluate safety, tolerability, and immunogenicity of heterologous regimens using the multivalent filovirus vaccines Ad26.Filo and MVA-BN-Filo administered in different sequences and schedules: A randomized, controlled study
by: Viki Bockstal, et al.
Published: (2022-01-01)

First-in-human study to evaluate safety, tolerability, and immunogenicity of heterologous regimens using the multivalent filovirus vaccines Ad26.Filo and MVA-BN-Filo administered in different sequences and schedules: A randomized, controlled study.
by: Viki Bockstal, et al.
Published: (2022-01-01)

Safety, reactogenicity, and immunogenicity of a 2-dose Ebola vaccine regimen of Ad26.ZEBOV followed by MVA-BN-Filo in healthy adult pregnant women: study protocol for a phase 3 open-label randomized controlled trial
by: Etienne Karita, et al.
Published: (2022-06-01)

Safety and immunogenicity of the heterologous prime-boost ebolavirus vaccine regimen CHAD3-EBO Z and MVA-BN (R) FILO in healthy UK adults
by: Rampling, T, et al.
Published: (2015)

NK Cell Subset Redistribution and Antibody Dependent Activation after Ebola Vaccination in Africans
by: Helen R. Wagstaffe, et al.
Published: (2022-05-01)

Optimal Expression, Function, and Immunogenicity of an HIV-1 Vaccine Derived from the Approved Ebola Vaccine, rVSV-ZEBOV
by: Hiva Azizi, et al.
Published: (2023-05-01)

Pregnancy Outcomes among Women Receiving rVSVΔ-ZEBOV-GP Ebola Vaccine during the Sierra Leone Trial to Introduce a Vaccine against Ebola
by: Jennifer K. Legardy-Williams, et al.
Published: (2020-03-01)

Artemisinin derivatives versus quinine in treating severe malaria in children: a systematic review
by: de Frey Albie, et al.
Published: (2008-10-01)

A monovalent chimpanzee adenovirus ebola vaccine boosted with MVA
by: Ewer (nee Russell), K, et al.
Published: (2016)

Systems Vaccinology Identifies an Early Innate Immune Signature as a Correlate of Antibody Responses to the Ebola Vaccine rVSV-ZEBOV
by: Anne Rechtien, et al.
Published: (2017-08-01)

Persistence of immunological memory as a potential correlate of long-term, vaccine-induced protection against Ebola virus disease in humans
by: Chelsea McLean, et al.
Published: (2023-09-01)

Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study
by: Huttner, A, et al.
Published: (2018)

Global blood miRNA profiling unravels early signatures of immunogenicity of Ebola vaccine rVSVΔG-ZEBOV-GP
by: Eleonora Vianello, et al.
Published: (2023-12-01)

Environmental Risk Assessment for rVSVΔG-ZEBOV-GP, a Genetically Modified Live Vaccine for Ebola Virus Disease
by: Joan G. Tell, et al.
Published: (2020-12-01)

Ring vaccination with rVSV-ZEBOV under expanded access in response to an outbreak of Ebola virus disease in Guinea, 2016: an operational and vaccine safety report.
by: Gsell, P, et al.
Published: (2017)

Vida, durante el mecanizado, del filo de herramientas de corte obtenidas mediante recubrimientos de c-BN+h-BN con diferentes estructuras
by: M. Kupczyk, et al.
Published: (2005-12-01)

Immune response of a two-dose heterologous Ebola vaccine regimen: summary of three African clinical trials using a single validated Filovirus Animal Nonclinical Group enzyme-linked immunosorbent assay in a single accredited laboratoryResearch in context
by: Chelsea McLean, et al.
Published: (2023-05-01)

Heterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1/1b trials
by: Myra Happe, et al.
Published: (2024-03-01)

A two-dose heterologous prime-boost vaccine regimen eliciting sustained immune responses to Ebola Zaire could support a preventive strategy for future outbreaks
by: Georgi Shukarev, et al.
Published: (2017-02-01)

Immune responses to novel adenovirus type 26 and modified vaccinia virus Ankara-vectored ebola vaccines at 1 year
by: Winslow, R, et al.
Published: (2017)

Safety and immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine in adults and children in Lambaréné, Gabon: A phase I randomised trial.
by: Selidji T Agnandji, et al.
Published: (2017-10-01)

Ebola Virus Glycoprotein IgG Seroprevalence in Community Previously Affected by Ebola, Sierra Leone
by: Daniela Manno, et al.
Published: (2022-03-01)

Indoor Air Pollution and Delayed Measles Vaccination Increase the Risk of Severe Pneumonia in Children: Results from a Case-Control Study in Mwanza, Tanzania.
by: George PrayGod, et al.
Published: (2016-01-01)

Transcriptomic signatures induced by the Ebola virus vaccine rVSVΔG-ZEBOV-GP in adult cohorts in Europe, Africa, and North America: a molecular biomarker study
by: Eleonora Vianello, PhD, et al.
Published: (2022-02-01)

Cittadini sul filo
by: Federico Rahola
Published: (2012-12-01)

Antibody-dependent natural killer cell activation after Ebola vaccination
by: Wagstaffe, HR, et al.
Published: (2019)